4.5 Article

Allergen immunotherapy for the prevention of allergic disease: protocol for a systematic review

期刊

PEDIATRIC ALLERGY AND IMMUNOLOGY
卷 27, 期 3, 页码 236-241

出版社

WILEY
DOI: 10.1111/pai.12524

关键词

allergy; allergic diseases; allergen immunotherapy; atopic; prevention; sensitization

资金

  1. Nestle
  2. ALK-Abello
  3. Allergy Therapeutics
  4. Circassia
  5. LETI
  6. Merck USA
  7. Allergopharma
  8. Bencard
  9. HAL
  10. Lovafarma
  11. Novartis
  12. Stallergenes
  13. Biotech Tools
  14. Lofarma
  15. Symbiopharm
  16. Stallergens
  17. GSK
  18. MERCK
  19. ABBVIE
  20. Menarini
  21. Meda
  22. Uriach
  23. Sanofi
  24. Menarini Meda
  25. ALK Abello
  26. HAL Allergy
  27. Artu Biologicals
  28. Allergy Therapeutics/Bencard
  29. Hartington
  30. Novartis/Leti
  31. GlaxoSmithKline
  32. Essex Pharma
  33. Cytos
  34. Curalogic
  35. Roxall
  36. Biomay
  37. Thermo Fisher
  38. European Union
  39. Biotech Tools s.a.
  40. Meda Pharma GmbH
  41. Stalleergenes
  42. Thermo-Fisher
  43. Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish
  44. Medical Research Council [G1000758, G0902018, MR/M008517/1] Funding Source: researchfish
  45. MRC [MR/M008517/1, G0902018] Funding Source: UKRI

向作者/读者索取更多资源

BackgroundThe European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Prevention of Allergic Disease. We seek to critically assess the effectiveness, cost-effectiveness, and safety of AIT in the prevention of allergic disease. MethodsWe will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesized. DiscussionThe findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据